XL765 (Exelixis, Inc., South San Francisco, CA USA) (Fig 1A) is an orally-active, potent and selective class-I PI3K/mTOR inhibitor which has demonstrated broad anti-cancer efficacy [44]. This evidence concerns the gene MTOR and cancer.